Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also revolutionized the treatment options for other B cell malignancies. Increasing evidence indicates that in addition to their...

Full description

Bibliographic Details
Main Authors: Sining Zhu, Samantha Gokhale, Jaeyong Jung, Eris Spirollari, Jemmie Tsai, Johann Arceo, Ben Wang Wu, Eton Victor, Ping Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
BTK
ibrutinib
acalabrutinib
immune cell subsets
immune responses
inflammation
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.727531/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.727531/full

Similar Items